You just read:

BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process

News provided by

BiondVax Pharmaceuticals Ltd.

Jun 10, 2019, 08:18 ET